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Abstract 
Review on TET2, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: KIAA1546, MDS 
HGNC (Hugo): TET2 
Location: 4q24 
Note: The name of the TET family ("ten eleven 
translocation") comes from the TET1 gene involved 
in the translocation t(10;11)(q21;q23) which fuses 
TET1 with MLL, in 2 cases of acute myeloid 
leukemia. 
DNA/RNA 
Description 
Genomic size: 133942bp; Coding sequence: 6009 nt 
- 11 exons, 9 coding exons on plus strand. 
Transcription 
From centromere to telomere. Pre-mRNA alternative 
splicing produces at least 3 isoforms. 
Protein 
Note 
Name: 2-oxoglutarate tet methylcytosine 
dioxygenase 2. 
Description 
The canonical isoform 1 is composed of 2002 amino 
acids. 
The catalytic dioxygenase domain is located at the 
C-terminal part of the protein, inside a cysteine-rich 
region.  
Isoforms 2 and 3 appear as truncated proteins whose 
function is not yet well understood. 
Expression 
Wide, mainly in haematopoietic tissues and in some 
specialized areas of the nervous tissue. 
Localisation 
Nuclear. 
Function 
Methylcytosine dioxygenase dependant of α-
ketoglutarate (α-KG, also called 2-oxoglutarate) and 
Fe++, which catalyses conversion from 5-
methylcytosine (5mC) to 5-
dihydroxymethylcytosine (5hmC).  
TET proteins play a key role in epigenetic regulation 
of the transcription.  
The transition from 5mC to 5hmC, and later to 5-
formylcytosine (5fC) and 5-carboxylcytosine 
(5caC), is considered as a key step in the process of 
DNA demethylation at CpG islands and other sites. 
The enrichment in 5hmC in CpG islands near or 
inside promoter sites, as well as in intragenic 
regions, leads to increased gene expression.  
5mC can be restored enzymatically from 5fC and 
5caC, but not from 5hmC.  
The global epigenetic regulation of transcription 
seems to depend on the dynamic balance between 
5mC and 5hmC (Branco et al., 2012; Kohli and 
Zhang, 2013) (figure 1). 
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The role of TET2 in haematopoiesis is pleiotropic, 
including self renewal of haematopoietic stem cells 
(HSCs), lineage commitment and cell line 
differentiation. TET2 is strongly expressed in 
progenitors and HSCs, and progressively repressed 
during differentiation. In mice the consequence of 
targeted inactivation of the Tet2 gene is a decrease 
of 5hmC and an increase of the number of mutated 
HSCs/progenitor cells, with a selective advantage 
over wt HSCs (Ko et al., 2011). 
TET2 and TET3 proteins have a strong interaction 
with O-GlcNac transferase (OGT), independent 
from their catalytic activity on 5mC. OGT mediates 
the addition of O-GlcNac to ser and thr residues of 
many intracellular proteins. The link TET2/3-OGT 
promotes the activity of OGT: this complex binds to 
chromatin and contributes to promoters activation by 
enrichment in histone H3K4me3 (Solary et al., 
2014). 
Tet1 and Tet2 are also expressed in murine 
embryonic stem cells. To be noted the role of murine 
Tet2, in conjunction with the enzyme poly(ADP-
ribose) polymerase-1 (Parp1), at an early stage of 
epigenetic reprogrammation of somatic cells into 
induced pluripotent stem cells (IPSCs) (Doege et al., 
2012). 
Homology 
TET2 is one member of a family comprising the 3 
evolutionary conserved genes TET1, TET2 and 
TET3 in mammals. Only TET1 and TET2 are 
involved in malignant haematological diseases. The 
3 proteins have two highly conserved domains in the 
middle of the protein and at the C-terminal 
extremity. TET1 and TET3 contain also a CXXC 
DNA binding zinc finger domain at the N-terminal 
extremity, which is not present in TET2. However 
there is a CXXC domain in a gene named CXXC4 or 
IDAX located 650kb proximal from TET2, which 
results from a chromosomal inversion affecting the 
ancestral TET2 gene. IDAX is oriented and 
transcribed in opposite direction from TET2, it 
regulates its expression and would be involved in its 
DNA binding (Ko et al., 2013). 
Mutations 
Note 
All types of somatic TET2 mutations were observed 
in cancer. The more prominent implication was 
described in haematological malignancies. However 
TET2 activity alteration, either by mutation or 
transcriptional mRNA reduction, was subsequently 
reported in a great variety of human tumours. 
The implication of the gene in haematological 
malignancies was first detected after the observation 
of reciprocal translocations involving a sub 
microscopic 4q24 deletion in tumour cells (Viguié et 
al., 2005). All mutations alter the catalytic activity, 
leading to a loss-of-function of the enzyme.  
Nonsense and frame shift mutations, which result in 
a truncated protein, occur all over the gene. But 
critical missense mutations occur only in the two 
evolutionary conserved domains of TET2. Missense 
variations outside of these two domains are 
considered as germinal polymorphisms. Both copies 
of the gene are altered in less than half of the 
patients, suggesting a role for haploinsufficiency. 
Consequently TET2 must be considered as a tumour 
suppressor gene.  
In murine models, the consequence of Tet2 
inactivation is a depletion of 5hmC in bone marrow 
cells, an increase of the pool of HSCs, and an 
orientation of maturation towards 
monocyte/macrophage differentiation (Quivoron et 
al., 2011). The same effect is obtained in vitro on 
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human cell lines or CD34+ cells, by shRNA 
knockdown of TET2 gene (Pronier et al., 2011). 
Mutations of TET2 and of IDH1/IDH2 are mutually 
exclusive, suggesting that they act in the same 
pathway. IDH1 and IDH2 are the two genes coding 
for an isocitrate deshydrogenase, they catalyse the 
decarboxylation of isocitrate to α-ketoglutarate (α-
KG) in the Krebs cycle. IDH mutations lead to a gain 
of function and the production of the R enantiomer 
of 2-hydroxyglutarate (R-2HG) instead of α-KG. As 
α-KG is a crucial cofactor for the activity of TET2, 
the protein is inactivated by the production of R-
2HG instead of α-KG. 
Mutations of IDH1/IDH2 are observed in many 
tumours including haematological malignancies 
with the same final epigenetic effect as TET2 
inactivation, mainly a global promoter 
hypermethylation. 
Implicated in 
Ph negative myeloproliferative 
neoplasms (MPN) 
Note 
Frequency: mutated in 10-16% of polycythemia 
vera, 4-11% of essential thrombocytemia, 7-17% of 
idiopathic myelofibrosis, 14% of myelofibrosis post 
PV or ET, 29% of mastocytosis. TET2 mutation is a 
very early event, preceding JAK2 mutation in the 
major part of cases with JAK2 V617F mutation. It is 
associated with the expansion of the mutated clone 
(Delhommeau et al., 2009; Tefferi et al., 2009b). 
However there is no notable correlation with 
prognosis. 
TET2 mutations were also observed during the 
progression from MPN to AML, appearing as a later 
event. 
Ph positive chronic 
myeloproliferative leukemia (CML) 
Note 
No TET2 mutation detected in chronic phase. 
In contrast mutations were detected in 8-12% of 
accelerated or blastic phase (Makishima et al., 2011; 
Roche-Lestienne et al., 2011). 
Chronic myelomonocytic leukemia 
(CMML) 
Note 
Frequency : TET2 mutated in 42-50%, being by far 
the most frequent molecular event in CMML. 
Prognosis 
Controversial. In some clinical studies CMML with 
TET2 mutated have a shorter overall survival and a 
higher monocyte rate compared to wt CMML. 
However other studies show less genomic alterations 
and a better prognosis in TET2 mutated patients 
(Tefferi et al., 2009a; Smith et al., 2010).  
Genome-wide DNA methylation studies show that 
TET2 mutated CMML express a lower level of 
hypermethylation than wt CMML and constitute a 
subtype with distinct epigenetic characteristics. 
Myelodysplastic syndrome (MDS) 
Note 
Frequency : TET2 mutated in 12-26%. As in 
CMML, TET2 mutation is the most frequent 
molecular event, before ASXL1 (~ 14%) and 
RUNX1 (~ 8%) mutations.  
There is no significant association with either sub-
type of MDS. However there is a correlation between 
TET2 mutation and MDS with a normal karyotype 
(Tefferi et al., 2009a; Langemeijer et al., 2009; 
Smith et al., 2010). 
Prognosis 
So far, no independent prognosis value. 
Acute myeloid leukemia (AML) 
Note 
Frequency : from 7 to 27% of primary AML. 
Prognosis 
The impact of TET2 mutations on AML prognosis is 
controversial. TET2 mutations are significantly 
associated with normal karyotype, older medium 
age, hyperleucocytosis and blasts rate more elevated. 
According to European Leukemia Net criteria, TET2 
mutation impairs the prognosis of cytogenetically 
normal AML with favourable risk (NPM1 and/or 
CEBPA mutated, FLT3-ITD negative), in 
comparison with wt-TET2 patients (Metzeler et al., 
2011).  
A more recent study from the EORTC group in AML 
patients<60 years, shows that a TET2 mutation is an 
independent factor of poor prognosis.  
TET2 mutations confer an even worse prognosis 
when associated with other bad prognosis factors 
(FLT3-ITD(+), -5, -7, complex).  
The same worse prognosis is observed when 
associated with a DNMT3A mutation.  
They also show that patients with low TET2 mRNA 
expression, albeit without mutation, have also a 
decrease of their overall survival (Aslanyan et al., 
2014). 
Blastic plasmacytoid dendritic cell 
neoplasm 
Note 
One study of 13 cases of this rare haematopoietic 
neoplasm of uncertain lineage showed TET2 frame 
shift, nonsense or missense mutations in 7 cases 
(53%).  
In 3 cases at least the mutations were biallelic (Jardin 
et al., 2011). 
Lymphoproliferative disease 
Note 
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Frequency: TET2 mutations were observed largely 
more frequently in T-cell lymphomas than in B-cell 
lymphomas (12% vs 2%). One to 3 TET2 mutations 
were found in 47 to 76% of angioimmunoblastic T-
cell lymphoma (AITL), often associated with 
mutations of DNMT3A, a gene involved in cytosine 
methylation. In peripheral not otherwise specified T-
cell lymphoma (PTCL-NOS), 38% harboured a 
TET2 mutation (Odejide et al., 2014). 
TET2 mutations can occur in early or advanced 
stages of lymphoid differentiation. Some patients 
have a concomitant or previous myelodysplastic 
syndrome, and the same TET2 mutation is found in 
both cell lineages, favouring a common origin from 
an early stem cell (Viguié et al., 2005; Delhommeau 
et al., 2009).  
More recently TET2 mutations were observed 
in12% of diffuse large B-cell lymphomas, composed 
of 5% missense and 7% nonsense mutations (Asmar 
et al., 2013). 
Low grade diffuse glioma 
Note 
More than 85% of low grade diffuse glioma have an 
IDH1/2 mutation. TET2 gene was explored in those 
lacking one of these two mutations. No TET2 
mutation was found but TET2 promoter methylation 
was detected in 5 of 35 cases (14%). No TET2 
alteration was observed in all cases with IDH1/2 
mutation (Kim et al., 2011). 
Other cancer types 
Note 
Some studies show that 5hmc reduction is 
significantly associated with tumorigenesis in a great 
variety of tumours, and that 5hmC depletion is 
frequently linked to a TET2 mutation or 
transcriptional inactivation, in cancers of breast, 
lung, pancreas, liver and probably colon and prostate 
(Yang et al., 2013). 
References 
Viguié F, Aboura A, Bouscary D, Ramond S, Delmer A, 
Tachdjian G, Marie JP, Casadevall N. Common 4q24 
deletion in four cases of hematopoietic malignancy: early 
stem cell involvement? Leukemia. 2005 Aug;19(8):1411-5 
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy 
S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi 
A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, 
Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, 
Fontenay M, Vainchenker W, Bernard OA. Mutation in TET2 
in myeloid cancers. N Engl J Med. 2009 May 
28;360(22):2289-301 
Langemeijer SM, Kuiper RP, Berends M, Knops R, 
Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen 
P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef 
GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte 
T, van der Reijden BA, Jansen JH. Acquired mutations in 
TET2 are common in myelodysplastic syndromes. Nat 
Genet. 2009 Jul;41(7):838-42 
Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, 
Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine 
RL. Detection of mutant TET2 in myeloid malignancies other 
than myeloproliferative neoplasms: CMML, MDS, 
MDS/MPN and AML. Leukemia. 2009a Jul;23(7):1343-5 
Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, 
Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, 
Hanson CA, Mesa R, Bernard O, Delhommeau F, 
Vainchenker W, Gilliland DG, Levine RL. TET2 mutations 
and their clinical correlates in polycythemia vera, essential 
thrombocythemia and myelofibrosis. Leukemia. 2009b 
May;23(5):905-11 
Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken 
J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter 
C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, 
Germing U, Mufti GJ. Next-generation sequencing of the 
TET2 gene in 355 MDS and CMML patients reveals low-
abundance mutant clones with early origins, but indicates 
no definite prognostic value. Blood. 2010 Nov 
11;116(19):3923-32 
Branco MR, Ficz G, Reik W. Uncovering the role of 5-
hydroxymethylcytosine in the epigenome. Nat Rev Genet. 
2011 Nov 15;13(1):7-13 
Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, 
Stamatoullas A, Leprêtre S, Penther D, Duval AB, 
Picquenot JM, Courville P, Capiod JC, Tilly H, Bastard C, 
Marolleau JP. TET2 and TP53 mutations are frequently 
observed in blastic plasmacytoid dendritic cell neoplasm. Br 
J Haematol. 2011 May;153(3):413-6 
Kim YH, Pierscianek D, Mittelbronn M, Vital A, Mariani L, 
Hasselblatt M, Ohgaki H. TET2 promoter methylation in low-
grade diffuse gliomas lacking IDH1/2 mutations. J Clin 
Pathol. 2011 Oct;64(10):850-2 
Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, 
Hastie R, Tsangaratou A, Rajewsky K, Koralov SB, Rao A. 
Ten-Eleven-Translocation 2 (TET2) negatively regulates 
homeostasis and differentiation of hematopoietic stem cells 
in mice. Proc Natl Acad Sci U S A. 2011 Aug 
30;108(35):14566-71 
Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, 
Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, 
Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette 
R, Maciejewski JP. CBL, CBLB, TET2, ASXL1, and IDH1/2 
mutations and additional chromosomal aberrations 
constitute molecular events in chronic myelogenous 
leukemia. Blood. 2011 May 26;117(21):e198-206 
Metzeler KH, Maharry K, Radmacher MD, Mrózek K, 
Margeson D, Becker H, Curfman J, Holland KB, Schwind S, 
Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, 
Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, 
Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. TET2 
mutations improve the new European LeukemiaNet risk 
classification of acute myeloid leukemia: a Cancer and 
Leukemia Group B study. J Clin Oncol. 2011 Apr 
1;29(10):1373-81 
Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon 
A, da Costa Reis Monte Mor B, Massé A, Le Couédic JP, 
Pendino F, Carbonne B, Larghero J, Ravanat JL, 
Casadevall N, Bernard OA, Droin N, Solary E, Godley LA, 
Vainchenker W, Plo I, Delhommeau F. Inhibition of TET2-
mediated conversion of 5-methylcytosine to 5-
hydroxymethylcytosine disturbs erythroid and 
granulomonocytic differentiation of human hematopoietic 
progenitors. Blood. 2011 Sep 1;118(9):2551-5 
Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, 
Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, 
Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd 
TET2 (tet methylcytosine dioxygenase 2) Viguié F 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(6) 409 
 
Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, 
Vainchenker W, Bastard C, Mercher T, Bernard OA. TET2 
inactivation results in pleiotropic hematopoietic 
abnormalities in mouse and is a recurrent event during 
human lymphomagenesis. Cancer Cell. 2011 Jul 
12;20(1):25-38 
Roche-Lestienne C, Marceau A, Labis E, Nibourel O, 
Coiteux V, Guilhot J, Legros L, Nicolini F, Rousselot P, 
Gardembas M, Helevaut N, Frimat C, Mahon FX, Guilhot F, 
Preudhomme C. Mutation analysis of TET2, IDH1, IDH2 
and ASXL1 in chronic myeloid leukemia. Leukemia. 2011  
Oct;25(10):1661-4 
Doege CA, Inoue K, Yamashita T, Rhee DB, Travis S, Fujita 
R, Guarnieri P, Bhagat G, Vanti WB, Shih A, Levine RL, Nik 
S, Chen EI, Abeliovich A. Early-stage epigenetic 
modification during somatic cell reprogramming by Parp1 
and Tet2. Nature. 2012 Aug 30;488(7413):652-5 
Asmar F, Punj V, Christensen J, Pedersen MT, Pedersen A, 
Nielsen AB, Hother C, Ralfkiaer U, Brown P, Ralfkiaer E, 
Helin K, Grønbæk K. Genome-wide profiling identifies a 
DNA methylation signature that associates with TET2 
mutations in diffuse large B-cell lymphoma. Haematologica. 
2013 Dec;98(12):1912-20 
Ko M, An J, Bandukwala HS, Chavez L, Aijö T, Pastor WA, 
Segal MF, Li H, Koh KP, Lähdesmäki H, Hogan PG, Aravind 
L, Rao A. Modulation of TET2 expression and 5-
methylcytosine oxidation by the CXXC domain protein 
IDAX. Nature. 2013 May 2;497(7447):122-6 
Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics 
of DNA demethylation. Nature. 2013 Oct 24;502(7472):472-
9 
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu 
HG, Ling ZQ, Ye D, Guan KL, Xiong Y. Tumor development 
is associated with decrease of TET gene expression and 5-
methylcytosine hydroxylation. Oncogene. 2013 Jan 
31;32(5):663-9 
Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-
Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, 
van de Locht LT, Tönnissen E, van der Heijden A, da Silva-
Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, 
Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van 
der Reijden BA, Suciu S, Jansen JH. Clinical and biological 
impact of TET2 mutations and expression in younger adult 
AML patients treated within the EORTC/GIMEMA AML-12 
clinical trial. Ann Hematol. 2014 Aug;93(8):1401-12 
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, 
Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, 
Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, 
Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri 
SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, 
Weinstock DM. A targeted mutational landscape of 
angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 
27;123(9):1293-6 
Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. 
The Ten-Eleven Translocation-2 (TET2) gene in 
hematopoiesis and hematopoietic diseases. Leukemia. 
2014 Mar;28(3):485-96 
This article should be referenced as such: 
Viguié F. TET2 (tet methylcytosine dioxygenase 2). Atlas 
Genet Cytogenet Oncol Haematol. 2015; 19(6):405-409. 
